Skip to content

Skin Irritation Test of Ten Products

Skin Irritation Test of Ten Products

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05245383
Enrollment
30
Registered
2022-02-17
Start date
2021-12-17
Completion date
2022-06-30
Last updated
2022-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitic Reaction of Face

Keywords

skin, skin health, allergen

Brief summary

Evaluation of cutaneous tolerance of ten products by primary irritant patch test

Detailed description

The purpose of this clinical study was the evaluation of skin irritation potential of ten products after a single application under occlusive patch on human skin.

Interventions

OTHERten products (S01~S10) and two blank (BK1, BK2)

S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* 20 to 70 years old, healthy male and female (sex ratio 1:1) * No acute or chronic diseases including skin diseases. * No current medications.

Exclusion criteria

* Pregnancy or breast feeding. * Abnormal blood test result/results (evaluation criteria: WBC, AST, ALT, and Creatinine) * Back skin with moles, acne, tattoo, scars, red spots, burns, etc. * Current dermatology medication which might affect skin condition evaluation. * Current irritated reaction on test site. * Participating in other clinical trial(s) within 7 days.

Design outcomes

Primary

MeasureTime frameDescription
Safety/Adverse Event Outcome MeasureUp to 48 hoursNumber of participants with Serous and Non-Serous Adverse Event
Total Number of Positive Responses Across All ParticipantsReading results at 30 minutes, 24 hours and 48 hours after the removal of the test products.Change from baseline of test products by using ICDRG (International Contact Dermatitis Research Group) grading

Countries

Taiwan

Contacts

Primary ContactSung-Jan Lin
drsjlin@ntu.edu.tw02 - 23123456
Backup ContactPo-Hua Chen
walile0425@gmail.com02 - 23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026